The ever expanding spinocerebellar ataxias. Editorial

Cerebellum

Volumn 11, Issue 4, 2012, Pages 821-827

  Matilla Dueñas, Antoni ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Ataxia scales; Cerebellum; Genetic counselling; Molecular diagnosis; Movement disorders; Neurodegeneration; Polyglutamine expansions; Purkinje cells; Rehabilitation; Spinocerebellar ataxias; Therapy

Indexed keywords

3,4 DIAMINOPYRIDINE; 5 HYDROXYTRYPTOPHAN; ACETAZOLAMIDE; AMANTADINE; BACLOFEN; BOTULINUM TOXIN; BUSPIRONE; CARBAMAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONAZEPAM; DOPAMINE RECEPTOR STIMULATING AGENT; GABAPENTIN; LAMOTRIGINE; MAGNESIUM; MEMANTINE; MEXILETINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PIRACETAM; QUININE; ROTIGOTINE; TANDOSPIRONE; TILIDINE; TIZANIDINE; VALPROIC ACID; VARENICLINE;

ARTICLE; ATAXIA; AUTOSOMAL DOMINANT INHERITANCE; BODY EQUILIBRIUM; BRAIN DEPTH STIMULATION; COGNITIVE DEFECT; COORDINATION; DEMENTIA; DISEASE SEVERITY; DYSTONIA; EPISODIC ATAXIA; FAMILY HISTORY; FRIEDREICH ATAXIA; GENE MUTATION; GENETIC COUNSELING; GENETIC HETEROGENEITY; GENETIC SCREENING; HUMAN; INVENTORY OF NON ATAXIA SYMPTOMS; MUSCLE CRAMP; MYOCLONUS; ONSET AGE; PHYSIOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; RATING SCALE; RESTLESS LEGS SYNDROME; SCALE FOR THE ASSESSMENT AND RATING OF ATAXIA; SPASTICITY; SPINOCEREBELLAR DEGENERATION;

CEREBELLUM; GENETIC TESTING; HUMANS; NEURODEGENERATIVE DISEASES; PATHOLOGY, MOLECULAR; SPINOCEREBELLAR ATAXIAS;

EID: 84870464151     PISSN: 14734222     EISSN: 14734230     Source Type: Journal    
DOI: 10.1007/s12311-012-0376-4     Document Type: Article

References (32)

1. Matilla-Dueñas A, Goold R, Giunti P. Molecular pathogenesis of spinocerebellar ataxias. Brain. 2006;129:1357-70. (Pubitemid 43999370)
2. Durr A. Autosomal dominant cerebellar ataxias: polyglutamine expansions and beyond. Lancet Neurol. 2010;9:885-94.
3. Matilla-Dueñas A, Sanchez I, Corral-Juan M, Davalos A, Alvarez R, Latorre P. Cellular and molecular pathways triggering neurodegeneration in the spinocerebellar ataxias. Cerebellum. 2010;9:148-66.
4. Matilla-Dueñas A. Machado-Joseph disease and other rare spinocerebellar ataxias. In: Ahmad S, editor. Neurodegenerative diseases. Austin: Landes Bioscience; 2012. p. 172-88.
5. Matilla-Dueñas A, Corral-Juan M, Volpini V, Sanchez I. The spinocerebellar ataxias: clinical aspects and molecular genetics. In: Ahmad SI, editor. Neurodegenerative diseases. Austin: Landes Bioscience; 2012. p. 351-74.
6. McKusick V (2010) Online Mendelian Inheritance in Man, OMIM (TM). McKusick-Nathans Institute of Genetic Medicine Johns Hopkins University (Baltimore, MD) and National Center for Biotechnology Information, National Library of Medicine, Bethesda, MD
7. Pagon RA, Bird TC, Dolan CR, Stephenson DA. Gene reviews [internet]. Seattle: University of Washington; 1993-2010.
8. Klockgether T. The clinical diagnosis of autosomal dominant spinocerebellar ataxias. Cerebellum. 2008;7:101-5.
9. Tsuji S, Onodera O, Goto J, Nishizawa M. Sporadic ataxias in Japan -a population-based epidemiological study. Cerebellum. 2008;7:189-97.
10. Erichsen AK, Koht J, Stray-Pedersen A, Abdelnoor M, Tallaksen CM. Prevalence of hereditary ataxia and spastic paraplegia in southeast Norway: a population-based study. Brain J Neurol. 2009;132:1577-88.
11. Velazquez Perez L, Cruz GS, Santos Falcon N, Almaguer Mederos LE, Escalona Batallan K, Rodriguez Labrada R, et al. Molecular epidemiology of spinocerebellar ataxias in Cuba: insights into SCA2 founder effect in Holguin. Neurosci Lett. 2009;454:157-60.
12. Schmitz-Hubsch T, du Montcel ST, Baliko L, Berciano J, Boesch S, Depondt C, et al. Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology. 2006;66:1717-20. (Pubitemid 43964628)
13. Schmitz-Hubsch T, Fimmers R, Rakowicz M, Rola R, Zdzienicka E, Fancellu R, et al. Responsiveness of different rating instruments in spinocerebellar ataxia patients. Neurology. 2011;74:678-84.
14. Schmitz-Hubsch T, Coudert M, Bauer P, Giunti P, Globas C, Baliko L, et al. Spinocerebellar ataxia types 1, 2, 3, and 6: disease severity and nonataxia symptoms. Neurology. 2008;71:982-9.
15. Chan E, Charles P, Ribai P, Goizet C, Marelli C, Vincitorio CM, et al. Quantitative assessment of the evolution of cerebellar signs in spinocerebellar ataxias. Mov Disord. 2011;26:534-8.
16. Jacobi H, Bauer P, Giunti P, Labrum R, Sweeney MG, Charles P, et al. The natural history of spinocerebellar ataxia type 1, 2, 3, and 6: a 2-year follow-up study. Neurology. 2011;77(11):1035-41.
17. Orr H, M-y C, Banfi S, Kwiatkowski Jr TJ, Servadio A, Beaudet AL, et al. Expansion of an unstable trinucleotide (CAG) repeat in spinocerebellar ataxia type 1. Nat Genet. 1993;4:221-6. (Pubitemid 23205168)
18. Kobayashi H, Abe K,Matsuura T, Ikeda Y, Hitomi T, Akechi Y, et al. Expansion of intronic GGCCTG hexanucleotide repeat in NOP56 causes SCA36, a type of spinocerebellar ataxia accompanied by motor neuron involvement. Am J Hum Genet. 2011;89:121-30.
19. Sequeiros J, Martindale J, Seneca S. EMQN Best Practice Guidelines for molecular genetic testing of SCAs. Eur J Hum Genet. 2010;18:1173-6.
20. Sequeiros J, Seneca S, Martindale J. Consensus and controversies in best practices for molecular genetic testing of spinocerebellar ataxias. Eur J Hum Genet. 2010;18:1188-95.
21. Ogawa M. Pharmacological treatments of cerebellar ataxia. Cerebellum. 2004;3:107-11. (Pubitemid 38797071)
22. Manto M, Marmolino D. Cerebellar ataxias. Curr Opin Neurol. 2009;22:419-29.
23. Trujillo-Martin MM, Serrano-Aguilar P, Monton-Alvarez F, Carrillo-Fumero R. Effectiveness and safety of treatments for degenerative ataxias: a systematic review. Mov Disord. 2009;24:1111-24.
24. Goizet C, Lesca G, Durr A. Presymptomatic testing in Huntington's disease and autosomal dominant cerebellar ataxias. Neurology. 2002;59:1330-6. (Pubitemid 35285982)
25. Watson MJ. Systematic review of the effectiveness of physiotherapy for cerebellar dysfunction. Clin Rehabil. 2009;23:764-5.
26. Ilg W, Synofzik M, Brotz D, Burkard S, Giese MA, Schols L. Intensive coordinative training improves motor performance in degenerative cerebellar disease. Neurology. 2009;73:1823-30.
27. Missaoui B, Thoumie P. How far do patients with sensory ataxia benefit from so-called "proprioceptive rehabilitation"? Neurophysiol Clin. 2009;39:229-33.
28. Corral-Juan M, Corral J, San Nicolás H, Volpini V, Matilla-Dueñas A. Genetics of the autosomal dominant spinocerebellar ataxias. In: eLS. Chichester: Wiley; 2011. doi:10.1002/9780470015902. a0006076.
29. Matilla-Dueñas A. Machado-Joseph disease and other rare spinocerebellar ataxias. In: Ahmad S, editor. Neurodegenerative diseases. Austin: Landes Bioscience; 2012. p. 172-88.
30. Matilla-Dueñas A, Corral-Juan M, Volpini V, Sanchez I. The spinocerebellar ataxias: clinical aspects and molecular genetics. In: Ahmad SI, editor. Neurodegenerative diseases. Austin: Landes Bioscience; 2012. p. 351-74.
31. Matilla-Dueñas A, Serrano C, Alvarez R, Ivánovic-Barbeito YP, Latorre P, Genís D. Novel therapeutic challenges in cerebellar diseases. In: Manto M, Gruol DL, Schmahmann JD, Koibuchi N, Rossi F, editors. Handbook of the cerebellum and cerebellar disorders. New York: Springer; 2012.
32. Subramony SH. Overview of autosomal dominant ataxias. In: Subramony SH, Dürr A, editors. Ataxic disorders. Handbook of clinical neurology, vol. 103. Edinburgh: Elsevier; 2012. 3rd series.